SORACOM
22.3.2022 13:02:10 CET | Business Wire | Press release
In keeping with its commitment to provide the most reliable and available connection for IoT devices deployed anywhere in the world, Soracom , Inc., a global provider of advanced IoT connectivity, today announced it has entered an agreement with Orange Wholesale France to expand its network for IoT connectivity around the world.
Soracom is delivering a highly competitive bundle of IoT connectivity and advanced network management capabilities. The partnership with Orange also enables Soracom to offer advanced IoT connectivity to innovators as an extension of Orange’s existing strong roaming partnerships across more than 220 destinations and 700 network operators.
Orange Wholesale France is the largest mobile network operator (MNO) in France and a leader in global IoT connectivity. Its unique international footprint, access to the best networks in terms of speed and coverage, and a wide range of connectivity options – including 2G, 3G, 4G, 5G, LPWA and upcoming new radio technologies – make it a strong partner as Soracom continues to grow.
With an expanding platform representing more than 4 million IoT connections around the world, Soracom is firmly committed to ensuring reliable connectivity wherever customer devices are deployed. This commitment extends not only to multiple redundant coverage layers wherever possible, as well as maximum coverage flexibility through support for eSIM, iSIM, and even UICC-compatible multi-IMSI solutions.
“From the very beginning, Soracom has focused on making advanced IoT connectivity accessible to any IoT innovator, anywhere in the world,” said Ken Tamagawa, Soracom CEO and co-founder. “This partnership with Orange Wholesale France allows us to bring the capability of France’s largest MNO to Soracom customers around the world, helping them accelerate time to market.”
“In the highly competitive European market for IoT connectivity services, providers need to offer more than just a contract for a certain amount of mobile data,” said Alexis Susset, Soracom vice president of global product and EU sales. “As a technology partner, Soracom is committed to delivering both the value and the technical capability that innovators need to succeed in IoT.”
“We are delighted to support Soracom’s international IoT expansion. Orange Wholesale France’s value proposition is all about trusted premium IoT connectivity for leading IoT MVNOs. This partnership with Soracom will bring innovation into the market and accelerate IoT growth on a large scale,” said Bénédicte Javelot, Orange Wholesale France CEO.
About Orange Wholesale France
Orange Wholesale France’s mission is to offer network solutions to all French and international operators and to market Orange's fixed and mobile infrastructures in France.
As a market leader with over 800 wholesale customers operators, Orange Wholesale France currently provides network infrastructure access to more than 1.2 million km of civil transmission arteries , broadband network access (copper and fiber) reaching nearly 40 million homes and businesses, including 13 million on third-party networks, mobile network access to all 2/3/4/5G mobile networks covering mainland France and French overseas territories as well as to more than 700 international roaming agreements worldwide.
It also offers IoT connectivity solutions all over the world to its international partners. Orange Wholesale France's 1,200 experts are committed every day to provide best-in-class solutions on networks that are monitored 24/7 with a dedicated customer support.
About Soracom
Soracom is leading the democratization of IoT connectivity, offering robust solutions specifically designed to make it easy to build, operate, and scale IoT deployments. Founded in 2015, Soracom now serves more than 20,000 startups, SMBs and global enterprises across all industries, from agriculture, energy, construction and transportation to consumer electronics, manufacturing, real estate and healthcare. Customers trust Soracom for affordable, reliable connectivity that accelerates speed to market, makes it easy to connect to the cloud, and offers access to a worldwide partner ecosystem. More information is available at www.soracom.io .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220322005318/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Consortium Led by Axelspace Selected for Japan’s Space Strategy Fund Project “Technology to Enhance Capability of Next Generation Earth Observation Satellites”30.3.2026 01:35:00 CEST | Press release
~ Creating Climate Solutions and New Market Opportunities through Source-Specific CO2 Emission and Uptake Monitoring via Satellite Constellation and Aircraft ~ Axelspace Corporation, Meisei Electric Co., Ltd., ANA HOLDINGS INC., and JIJ Inc. are pleased to announce that their jointly proposed technology development project has been selected for Japan Aerospace Exploration Agency (JAXA)’s Space Strategy Fund under the theme “Technology to Enhance Capability of Next Generation Earth Observation Satellites.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260323044518/en/ Conceptual Diagram of the project. Under this Space Strategy Fund initiative, spectrometers will be newly developed and demonstrated in orbit. In the future, the project envisions the establishment of a satellite constellation capable of observations at different times of the day. Project Summary (Planned) Technology Development Theme: Technology to Enhance Cap
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom